Lu J - Search Results

1

Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.

Marconi V, Bonhoeffer S, Paredes R, Lu J, Hoh R, Martin JN, Deeks SG, Kuritzkes DR. Marconi V, et al. Among authors: lu j. J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):572-6. doi: 10.1097/QAI.0b013e31817bbc4e. J Acquir Immune Defic Syndr. 2008. PMID: 18645515 Free PMC article.

2

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR. Lu J, et al. J Virol. 2004 May;78(9):4628-37. doi: 10.1128/jvi.78.9.4628-4637.2004. J Virol. 2004. PMID: 15078945 Free PMC article.

3

Effect of the Q207D mutation in HIV type 1 reverse transcriptase on zidovudine susceptibility and replicative fitness.

Lu J, Whitcomb J, Kuritzkes DR. Lu J, et al. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):20-3. doi: 10.1097/01.qai.0000172369.82456.36. J Acquir Immune Defic Syndr. 2005. PMID: 16123676

4

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.

Lu J, Deeks SG, Hoh R, Beatty G, Kuritzkes BA, Martin JN, Kuritzkes DR. Lu J, et al. J Acquir Immune Defic Syndr. 2006 Sep;43(1):60-4. doi: 10.1097/01.qai.0000234083.34161.55. J Acquir Immune Defic Syndr. 2006. PMID: 16885776

5

Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.

Marcial M, Lu J, Deeks SG, Ziermann R, Kuritzkes DR. Marcial M, et al. Among authors: lu j. J Clin Microbiol. 2006 Sep;44(9):3384-7. doi: 10.1128/JCM.00666-06. J Clin Microbiol. 2006. PMID: 16954280 Free PMC article.

6

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.

Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR. Deeks SG, et al. Among authors: lu j. J Infect Dis. 2007 Feb 1;195(3):387-91. doi: 10.1086/510531. Epub 2006 Dec 21. J Infect Dis. 2007. PMID: 17205477 Clinical Trial.

7

Continued evolution in gp41 after interruption of enfuvirtide in subjects with advanced HIV type 1 disease.

Kitchen CM, Lu J, Suchard MA, Hoh R, Martin JN, Kuritzkes DR, Deeks SG. Kitchen CM, et al. Among authors: lu j. AIDS Res Hum Retroviruses. 2006 Dec;22(12):1260-6. doi: 10.1089/aid.2006.22.1260. AIDS Res Hum Retroviruses. 2006. PMID: 17209769

8

Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen.

Cohan D, Feakins C, Wara D, Petru A, McNicholl I, Schillinger D, Lu J, Kuritzkes D, Deeks SG. Cohan D, et al. Among authors: lu j. AIDS. 2005 Jun 10;19(9):989-90. doi: 10.1097/01.aids.0000171417.84162.af. AIDS. 2005. PMID: 15905684 No abstract available.

9

Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.

Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Hu Z, et al. Among authors: lu j. J Virol. 2006 Jul;80(14):7020-7. doi: 10.1128/JVI.02747-05. J Virol. 2006. PMID: 16809307 Free PMC article.

10

A novel recombinant marker virus assay for comparing the relative fitness of hiv-1 reverse transcriptase variants.

Lu J, Kuritzkes DR. Lu J, et al. J Acquir Immune Defic Syndr. 2001 May 1;27(1):7-13. doi: 10.1097/00126334-200105010-00002. J Acquir Immune Defic Syndr. 2001. PMID: 11404514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33,671 results

Search Page

Filters